Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Florida
Clinical trial register · United States · industry-sponsored

Clinical Trials in Florida, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 63 Georgia 57 Florida 56 Colorado 41 Arizona 38
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC13 Pfizer8 AbbVie7 GlaxoSmithKline4 Celgene3
State
California63 Georgia57 Florida56 Colorado41 Arizona38
All 42 states
Target enrolment
to

Trials with a site in Florida

56 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-31
Recruiting
GlaxoSmithKline
Phase 2
200
California, Connecticut, Florida, Georgia, Louisiana, Maryland, Missouri, New Mexico
2026-04-15
Recruiting
AbbVie
Phase 1
127
California, Colorado, Florida, Georgia, Illinois, Michigan
2026-02-27
Recruiting
C4 Therapeutics, Inc.
Phase 2
100
Alabama, Arizona, California, Florida, Georgia, Indiana, Iowa, Michigan
2026-02-18
Active, closed
Janssen Research & Development, LLC
Phase 2
168
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2026-02-08
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-02-04
Recruiting
Janssen Research & Development, LLC
Phase 2
60
California, Florida, Iowa, New York, North Carolina, Ohio
2025-10-03
Recruiting
AstraZeneca
Phase 1
40
Arizona, California, Colorado, Florida, Georgia, Iowa, Minnesota, Missouri
2025-07-31
Recruiting
AbbVie
Phase 1/2
602
California, Colorado, Florida, Georgia, New York, North Carolina, Ohio, Texas
2025-06-30
Recruiting
GlaxoSmithKline
Phase 3
520
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Maine
2024-12-16
Active, closed
Cullinan Therapeutics Inc.
Phase 1
30
Arizona, Florida, Minnesota, New York, North Carolina, Texas
2024-09-03
Active, closed
Kite, A Gilead Company
Phase 3
452
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2024-08-23
Active, closed
AbbVie
Phase 1
60
Arizona, Florida, Michigan, Minnesota, North Carolina, Wisconsin
2024-06-17
Active, closed
Janssen Research & Development, LLC
Phase 1
108
Arizona, Colorado, Florida, Georgia, Indiana, Ohio, Texas
2024-06-07
Active, closed
AbbVie
Phase 3
421
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana
2024-05-19
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
230
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-03-21
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
187
Alabama, Arizona, California, Florida, Georgia, Massachusetts, Minnesota, Nebraska
2024-02-22
Active, closed
Pfizer
Phase 1
100
Florida, Georgia, Indiana, Maryland, Massachusetts, Nebraska, New Hampshire, New Jersey
2024-02-20
Recruiting
Pfizer
Phase 3
492
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas
2024-02-08
Active, closed
Janssen Research & Development, LLC
Phase 3
838
California, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Iowa
2024-01-22
Recruiting
Indapta Therapeutics, INC.
Phase 1/2
128
California, Florida, Georgia, Minnesota, New York, North Carolina, Ohio, Oregon
2023-10-25
Active, closed
Celgene
Phase 3
79
California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan, Minnesota
2023-10-16
Recruiting
Pfizer
Phase 4
80
California, Colorado, Florida, Michigan, Texas
2023-10-03
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Colorado, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2023-06-22
Recruiting
GlaxoSmithKline
Phase 1/2
123
Arizona, California, Florida, Massachusetts, Michigan, North Carolina, Ohio, Tennessee
2023-06-14
Active, closed
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
NCT05673083Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory, Multiple Myeloma With Failed Remission
All4Cure
Observational
200
Arkansas, Florida, Iowa, New York, Oklahoma, Texas, Washington
2023-03-01
Recruiting
K36 Therapeutics, Inc.
Phase 1
165
California, Florida, Georgia, Massachusetts, Minnesota, New Jersey, New York, North Carolina
2023-02-22
Active, closed
Janssen Research & Development, LLC
Phase 3
213
Florida, Georgia, Michigan, Missouri, New York, Texas
2022-12-15
Active, closed
Pfizer
Phase 1
59
Arkansas, California, Florida, Georgia, Iowa, Maryland, Massachusetts, New Jersey
2022-12-14
Recruiting
Pfizer
Phase 3
1,060
Florida, Nebraska, Nevada, New Jersey, New York, Texas, Utah
2022-11-10
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa
2022-10-25
Active, closed
Hoffmann-La Roche
Phase 1/2
90
Colorado, Florida, Maryland, Massachusetts, Minnesota, New York, Tennessee, Utah
2022-10-17
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Arizona, Arkansas, Connecticut, District of Columbia, Florida, Illinois, Kansas, Louisiana
2022-10-13
Active, closed
Kite, A Gilead Company
Phase 2
136
Arizona, Arkansas, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2022-07-15
Active, closed
Celgene
Phase 3
939
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2022-06-23
Active, closed
Pfizer
Phase 3
854
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kansas, Michigan
2022-03-25
Recruiting
Janssen Research & Development, LLC
Phase 4
295
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Massachusetts
2022-03-09
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
California, Colorado, District of Columbia, Florida, Illinois, Maryland, Massachusetts, New Jersey
2022-02-28
Recruiting
Pfizer
Phase 3
893
California, Colorado, Florida, Louisiana, New Jersey, New York
2021-10-04
Active, closed
Janssen Research & Development, LLC
Phase 3
743
California, Connecticut, Florida, Iowa, Kentucky, Maryland, Massachusetts, Michigan
2021-08-19
Active, closed
C4 Therapeutics, Inc.
Phase 1
224
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Minnesota, Missouri
2021-04-27
Active, closed
Pfizer
Phase 2
187
California, Florida, Georgia, Illinois, Kentucky, Louisiana, New Jersey, New York
2021-02-02
Active, closed
GlaxoSmithKline
Phase 3
302
Arizona, Florida, Massachusetts, Missouri, Tennessee
2020-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
419
Alabama, Arizona, California, Colorado, Connecticut, Florida, Iowa, Kansas
2020-06-12
Active, closed
Janssen Research & Development, LLC
Phase 2
208
California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Kansas
2019-11-07
Active, closed
Celgene
Phase 1/2
424
Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota, New Jersey
2019-09-30
Active, closed
CARsgen Therapeutics Co., Ltd.
Phase 1/2
105
Arizona, California, Colorado, Florida, Massachusetts, Minnesota, Tennessee, Texas
2019-09-25
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
387
Florida, Georgia, Indiana, Kentucky, Michigan, New Jersey, New York, Ohio
2019-01-23
Active, closed
AbbVie
Phase 3
265
Arizona, California, Colorado, Florida, Kentucky, Maryland, Massachusetts, Michigan
2018-10-22
By invitation
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
NCT03628612Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric
Autolus Limited
Phase 2
500
Florida, Missouri, Texas
2018-08-02
Active, closed
AbbVie
Phase 2
156
Colorado, Florida, Georgia, Illinois, Massachusetts, New Jersey, New York, North Carolina
2018-04-02
Active, closed
BioLineRx, Ltd.
Phase 3
180
California, Florida, Illinois, Maryland, Minnesota, Missouri, Ohio, Texas
2018-03-23
Active, closed
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
NCT02952508Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugCLR 131
Cellectar Biosciences, Inc.
Phase 2
120
California, District of Columbia, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2017-07-26
Recruiting
Oncotherapeutics
Phase 1
134
California, Florida, Maryland, Washington
2017-02-01
Active, closed
AbbVie
Phase 2
120
Alabama, Arkansas, Florida, Georgia, Illinois, Indiana, Kentucky, Maine
2017-01-19
Active, closed
Bristol-Myers Squibb
Observational
2,555
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Iowa
2012-06-13
Rows per page Showing 1–56 of 56
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-usa/state/florida

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 10 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 56 of those studies with a site in Florida that also match the filters currently applied.

How many clinical trials are recruiting in Florida?

23 of the 56 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 32 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Florida), 56 studies
PhaseStudiesRecruitingShare
Phase 321737.5%
Phase 212421.4%
Phase 111519.6%
Phase 1/28514.3%
Observational203.6%
Phase 4223.6%

Most active sponsors

Lead sponsors with the most studies (Florida)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC135
Pfizer84
AbbVie72
GlaxoSmithKline43
Celgene30
Bristol-Myers Squibb20
C4 Therapeutics, Inc.21
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company22
Kite, A Gilead Company20
All4Cure10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.